{
    "info": {
        "nct_id": "NCT03126019",
        "official_title": "A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)",
        "inclusion_criteria": "* Aged 18 years or older.\n* Histologically confirmed, relapsed or refractory, follicular B-cell non-Hodgkin lymphoma (NHL) (follicular lymphoma) Grade 1, 2, and 3a.\n* Ineligible for hematopoietic stem cell transplant.\n* Must have been treated with at least 2 prior systemic therapies.\n* Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures > 1.5 cm in the longest dimension and ≥ 1.0 cm in the longest perpendicular dimension as assessed by computed tomography or magnetic resonance imaging.\n* Must be willing to undergo an incisional, excisional, or core needle lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known histological transformation from indolent NHL to diffuse large B-cell lymphoma.\n* History of central nervous system lymphoma (either primary or metastatic).\n* Prior treatment with idelalisib, other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors, or a pan-PI3K inhibitor.\n* Prior treatment with a Bruton's tyrosine kinase inhibitor (eg, ibrutinib).\n* Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of study treatment administration.\n* Active graft-versus-host disease.\n* Participants positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for hepatitis B virus-deoxyribonucleic acid (HBV-DNA). Participants positive for anti-hepatitis C virus (HCV) antibody will be eligible if they are negative for HCV-ribonucleic acid (RNA).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Must have been treated with at least 2 prior systemic therapies.",
            "criterions": [
                {
                    "exact_snippets": "treated with at least 2 prior systemic therapies",
                    "criterion": "prior systemic therapies",
                    "requirements": [
                        {
                            "requirement_type": "number of prior treatments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures > 1.5 cm in the longest dimension and ≥ 1.0 cm in the longest perpendicular dimension as assessed by computed tomography or magnetic resonance imaging.",
            "criterions": [
                {
                    "exact_snippets": "Radiographically measurable lymphadenopathy",
                    "criterion": "lymphadenopathy",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "computed tomography",
                                "magnetic resonance imaging"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Radiographically measurable ... extranodal lymphoid malignancy",
                    "criterion": "extranodal lymphoid malignancy",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "computed tomography",
                                "magnetic resonance imaging"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of ≥ 1 lesion that measures > 1.5 cm in the longest dimension and ≥ 1.0 cm in the longest perpendicular dimension",
                    "criterion": "lymphoid lesion size",
                    "requirements": [
                        {
                            "requirement_type": "number of lesions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "longest dimension",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "longest perpendicular dimension",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aged 18 years or older.",
            "criterions": [
                {
                    "exact_snippets": "Aged 18 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed, relapsed or refractory, follicular B-cell non-Hodgkin lymphoma (NHL) (follicular lymphoma) Grade 1, 2, and 3a.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed",
                    "criterion": "diagnosis confirmation",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "histology"
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed or refractory",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "follicular B-cell non-Hodgkin lymphoma (NHL) (follicular lymphoma)",
                    "criterion": "disease type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "follicular B-cell non-Hodgkin lymphoma"
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade 1, 2, and 3a",
                    "criterion": "disease grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "1",
                                "2",
                                "3a"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ineligible for hematopoietic stem cell transplant.",
            "criterions": [
                {
                    "exact_snippets": "Ineligible for hematopoietic stem cell transplant",
                    "criterion": "hematopoietic stem cell transplant eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must be willing to undergo an incisional, excisional, or core needle lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue.",
            "criterions": [
                {
                    "exact_snippets": "Must be willing to undergo an incisional, excisional, or core needle lymph node or tissue biopsy",
                    "criterion": "willingness to undergo lymph node or tissue biopsy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "biopsy_type",
                            "expected_value": [
                                "incisional",
                                "excisional",
                                "core needle"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "or provide a lymph node or tissue biopsy from the most recent available archival tissue",
                    "criterion": "provision of lymph node or tissue biopsy from most recent available archival tissue",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "most recent available archival tissue"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* History of central nervous system lymphoma (either primary or metastatic).",
            "criterions": [
                {
                    "exact_snippets": "History of central nervous system lymphoma (either primary or metastatic)",
                    "criterion": "central nervous system lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known histological transformation from indolent NHL to diffuse large B-cell lymphoma.",
            "criterions": [
                {
                    "exact_snippets": "Known histological transformation from indolent NHL to diffuse large B-cell lymphoma",
                    "criterion": "histological transformation from indolent NHL to diffuse large B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active graft-versus-host disease.",
            "criterions": [
                {
                    "exact_snippets": "Active graft-versus-host disease",
                    "criterion": "graft-versus-host disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with idelalisib, other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors, or a pan-PI3K inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with idelalisib",
                    "criterion": "idelalisib treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors",
                    "criterion": "selective PI3Kδ inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... pan-PI3K inhibitor",
                    "criterion": "pan-PI3K inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of study treatment administration.",
            "criterions": [
                {
                    "exact_snippets": "Allogeneic stem cell transplant within the last 6 months",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "autologous stem cell transplant within the last 3 months",
                    "criterion": "autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for hepatitis B virus-deoxyribonucleic acid (HBV-DNA). Participants positive for anti-hepatitis C virus (HCV) antibody will be eligible if they are negative for HCV-ribonucleic acid (RNA).",
            "criterions": [
                {
                    "exact_snippets": "Participants positive for hepatitis B surface antigen or hepatitis B core antibody ... will be eligible if they are negative for hepatitis B virus-deoxyribonucleic acid (HBV-DNA)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "serostatus",
                            "expected_value": [
                                "positive for hepatitis B surface antigen",
                                "positive for hepatitis B core antibody"
                            ]
                        },
                        {
                            "requirement_type": "HBV-DNA status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants positive for anti-hepatitis C virus (HCV) antibody ... will be eligible if they are negative for HCV-ribonucleic acid (RNA)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "serostatus",
                            "expected_value": "positive for anti-hepatitis C virus (HCV) antibody"
                        },
                        {
                            "requirement_type": "HCV-RNA status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with a Bruton's tyrosine kinase inhibitor (eg, ibrutinib).",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with a Bruton's tyrosine kinase inhibitor (eg, ibrutinib)",
                    "criterion": "prior treatment with Bruton's tyrosine kinase inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}